HealthStream (HSTM)
(Delayed Data from NSDQ)
$25.61 USD
-0.31 (-1.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.60 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
HSTM 25.61 -0.31(-1.20%)
Will HSTM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HSTM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HSTM
5 Stocks With Recent Dividend Hike to Watch Amid Volatility
Lyft (LYFT) Tops Q4 Earnings and Revenue Estimates
HSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zscaler, Inc. (ZS) Hits Fresh High: Is There Still Room to Run?
HealthStream (HSTM) Beats Q3 Earnings Estimates
HealthStream (HSTM) Tops Q2 Earnings and Revenue Estimates
Other News for HSTM
HealthStream (NASDAQ:HSTM): Strong Financial Results in a Fast-Growing Sector
HealthStream Inc (HSTM) Q1 2024 Earnings Call Transcript Highlights: Impressive Growth and ...
Analysts Conflicted on These Healthcare Names: HealthStream (HSTM) and Option Care Health (OPCH)
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
Barclays Sticks to Its Buy Rating for HealthStream (HSTM)